2015 Volume 34 Issue 2 Pages 108-115
In April 2014, a Letter of Rapid Safety Communication was issued, because 21 fatalities following administration of paliperidone palmitate (PP) were reported over a 5-month period since its launch in November, 2013. At the Department of Pharmacy of Hakodate Watanabe Hospital (our hospital), we established criteria for the use of long-acting antipsychotic injections (LAIs) when we began to prescribe LAIs at our hospital and shared information on the use of LAIs with pharmacists at community pharmacies by placing seals in medication notebooks. In March 2014, we conducted a questionnaire survey of pharmacists at 223 community pharmacies in Southern Hokkaido to compared the investigation items by the percentage of prescriptions filled in by the department of psychiatry among all the prescriptions dispensed by the pharmacies. The pharmacists who answered that injectable drug use information and seals for medication notebooks were necessary accounted for 75.8% and 74.2% of the responders, respectively. On the other hand, the percentages comprising the acquisition rates of information on injectable drug use and information on the injectable drugs used were low with 12.1% and 7.6% respectively. Also, a significant difference was seen in the recognition of LAI use in the comparison by the percentage of prescriptions filled in by the department of psychiatry among all of the prescriptions dispensed by the pharmacies (p＝0.001). Our results show that collaboration between hospital pharmacists and community pharmacists is necessary to ensure the safe use of LAI.
